Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Roprestine N01 for chemoradiotherapy-induced thrombocytopenia
ChiCTR2600128509Phase 4Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), radiotherapy-induced thrombocytopenia (RIT) and Thrombocytopenia, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: platelet count. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)radiotherapy-induced thrombocytopenia (RIT)Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2600128509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128509.